Vor Biopharma's trem-cel offers hope for AML treatment, but financial risks and early-stage progress suggest caution. Learn ...

the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts while maintaining healthy blood count levels and change the standard ...

Officer of Vor Biopharma Inc. (NASDAQ:VOR), recently sold shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The transaction, which occurred on ...

在其他近期新闻中，生物技术公司Vor Biopharma Inc.对某些股票期权的行权价格进行了重大调整。公司董事会批准将在职员工的未行使股票期权行权价格降至每股$1.34。此次重新定价影响了公司2015年、2021年和2023年激励计划下行权价格高于$1.34的期权。